MYRIAD GENETICS INC — Director's Dealing 2022

Feb 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MYRIAD GENETICS INC (MYGN)
CIK: 0000899923
Period of Report: 2022-02-16

Reporting Person: Verratti Mark (President, Mental Health)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-16	Common Stock	A	22616	$0.0	Acquired	216635	Direct

Footnotes

F1: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on March 24, 2021, subject to accomplishment of pre-determined performance metrics. On February 16, 2022, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on March 24, 2022, 25% on March 24, 2023, 25% on March 24, 2024, and 25% on March 24, 2025.